N(6)-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

Colorectal cancer (CRC) is one of the most prevalent cancers and one of the leading causes of cancer death. Recent studies have provided evidence that N(6)-methyladenosine (m(6)A), the most abundant RNA modifications in eukaryote, performs many functions in RNA metabolism including translation, spli...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jinming, Liang, Lei, Yang, Yongzhi, Li, Xinxiang, Ma, Yanlei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806471/
https://www.ncbi.nlm.nih.gov/pubmed/33456561
http://dx.doi.org/10.7150/thno.52366
Descripción
Sumario:Colorectal cancer (CRC) is one of the most prevalent cancers and one of the leading causes of cancer death. Recent studies have provided evidence that N(6)-methyladenosine (m(6)A), the most abundant RNA modifications in eukaryote, performs many functions in RNA metabolism including translation, splicing, storage, trafficking and degradation. Aberrant regulation of m(6)A modification in mRNAs and noncoding RNAs found in CRC tissues is crucial for cancer formation, progression, invasion and metastasis. Further, m(6)A regulators and m(6)A-related RNAs may become promising biomarkers, prognosis predictors as well as therapeutic targets. Here, we review the biological and clinical roles of m(6)A modification in CRC, and discuss the potential of m(6)A in clinical translation.

Ejemplares similares